|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
|
Ƥ���� |
|
���� |
| ��������������� | |
|
����� |
|
��־ǿ |
| PubMed | |
|
Article by |
|
Article by |
�������ؼ�����Ƥ���������е�����
�����, ��־ǿ
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
��������Ϊһ�ּ�߿��������������Ե�����������������,�俹���������ߵĻ����������ͬ��ҩ�ﲻͬ.��ҩ����������Ӧ�õ�����������ҩ��ͬ���ƵĿ���������.Ŀǰ,��ҩ�������ʪ�Թؽ���������ȡ��һ���ijɹ�,����Խ��Խ����������������ԡ���֢�Լ�������Ƥ������������.
[2] Schorlemmer HU,Milbert U,Zeitter D,et al.Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.Inflamm Res,1999,48(Suppl 2);Sl15-Sl16.
[3] Nousari HC,Anhalt GJ.Bullous pemphigoid treated with leflunomide:a novel immunomodulatory agent.Arch Dermatol,2000,136(10):1204-1205.
[4] Hamilton LC,Vojnovic I,Warner TD.A771726,the active metabolite of leflunomide,directly inhibits the activity of cyclo-oxygenase-2 in vitro and in viyo in a substrate-sensitive manner.Br J Pharmacol,1999,127(7);1589-1596.
[5] Alldred A,Emery P.Leflunomide:a novel DMARD for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2001,2(1):125-137.
[6] Jankovic V,Samardzic T,Stosic-Grujicic S,et al.Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.Cell Immunol,2000,199(2):73-80.
[7] Waldman WJ,Bickerstaff A,Gordillo G,et al.Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide.Transplantation,2001,72(9):1578-1582.
[8] Kraan MC,de Koster BM,Elferink JG,et al.Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis:findings in a prospective,randomized,double-blind clinical trial in fifteen patients.Arthritis Rheum,2000,43(7);1488-1495.
[9] Herrmann ML,Schleyerbach R,Kirschbaum BJ.Leflunomide:an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.Immunopharmacology,2000,47(2-3):273-289.
[10] Mizushima Y,Amano Y,Kitagawa H,et al.Oral administration of leflunomide(HWA486)results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.J Pharmacol Exp Ther,1999,288(2);849-857.
[11] Coblyn JS,Shadick N,Helfgott S.Leflunomide-associated weight loss in rheumatoid arthritis.Arthritis Rheum,2001,44(5);1048-1051.
[12] Brent RL.Teratogen update:reproductive risks of leflunomide(Arava);a pyrimidine synthesis inhibitor:counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child.Teratology,2001,63(2):106-112.
[13] Weinblatt ME,Dixon JA,Falchuk KR.Serious liver disease in a patient receiving methotrexate and leflunomide.Arthritis Rheum,2000,43(11);2609-2611.
[14] Schiff MH,Whelton A.Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.Semin Arthritis Rheum,2000,30(3):196-208.
[15] Auer J,Hinterreiter M,Allinger S,et al.Severe pancytopenia after leflunomide in rheumatoid arthritis.Acta Med Austriaca,2000,27(4);131-132.
[16] Weinblatt ME,Kremer JM,Coblyn JS,et al.Pharmacokinetics,safety,and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.Arthritis Rheum,1999,42(7);1322-1328.
[17] Remer CF,Weisman MH,Wallace DJ.Benefits of leflunomide in systemic lupus eryth ematosus:a pilot observational study.Lupus,2001,10(7);480-483.
[18] Mirmohammadsadegh A,Homey B,Abts HF,et al.Differential modulation of pro-and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide(A77 1726),the physiologically active metabolite of the novel immunomodulator leflunomide.Biochem Pharmacol,1998,55(9);1523-1529.
[19] Waldman WJ,Knight DA,Blinder L,et al.Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.Intervirology,1999,42(5-6);412-418.
[20] Knight DA,Hejmanowski AQ,Dierksheide JE,et al.Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide.Transplantation,2001,71(1);170-174.
[21] Cohen Tervaert JW,Stegeman CA,Kallenberg CG.Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.Curr Opin Nephrol Hypertens,2001,10(2):211-217.
[22] Scott DL,Smolen JS,Kalden JR,et al.Treatment of active rheumatoid arthritis with leflunomide:two year follow up of a double blind,placebo controlled trial versus sulfasalazine.Ann Rheum Dis,2001,60(10);913-923.